Grouping of anticancer drugs based on administration method-related toxicity patterns in rats

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4611-4614

  Mizushima, Yutaka ^a   Hui, Li ^a   Sassa, Kazuhiko ^a   Fujishita, Takashi ^a   Oosaki, Rokuo ^a   Kobayashi, Masashi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Administration method; Anticancer drug; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; MITOMYCIN C; NIMUSTINE; VINDESINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG USE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CARBOPLATIN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENOUS; MALE; MITOMYCIN; NIMUSTINE; RATS; RATS, INBRED F344; TRANSPLANTATION, ISOGENEIC; VINDESINE;

EID: 2642590961     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Masuda N, Fukuoka M, Furuse K: CODE chemotherapy with or without recombinant human granulocyte colony stimulating factor in extensive-stage small cell lung cancer. Oncology 49 (suppl 1): 19-24, 1992.
2. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A: 319-324, 1993.
3. Safirsten R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J: Cisplatin nephrotoxicity. Am J Kidney Dis 8: 356-367, 1986.
4. Mizushima Y, Konishi K, Morikage T, Yano S: Importance of administration method in high-dose anticancer chemotherapy from toxicological standpoint in rats. Oncology 48: 431-437, 1991.
5. Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Blumenschein GR: Pulmonary toxicity of mitomycin. Cancer 45: 236-244, 1980.
6. Verweiji J, van Zanten T, Souren T, Golding R, Pinedo HM: Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer 60: 756-761, 1987.
7. Liebermann A, Ruoff M, Estey E, Seidman I, Liebermann I, Wise A: Irreversible pulmonary toxicity after single course of ACNU. Am J Med Sci 279: 53-56, 1980.
8. Litam JP, Dail DH, Spitzer G, Vellekoop L, Zander AR, Dicke KA: Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep 65: 39-44, 1981.
9. Ohnuma T, Greenspan EM, Holland JF: Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion. Cancer Treat Rep 64: 25-30, 1980.
10. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
11. Panici PB, Scambia G, Baiocchi G, et al: Rationale for very high-dose chemotherapy with peripheral blood stem cell support in advanced ovarian cancer. Haematologica 75 (suppl 1): 87-89, 1990.
12. Kessinger A, Armitage J, Bierman P, et al: Clinical outcome of peripheral blood stem cell support. Med Oncol 11: 43-46, 1994.